Dual PPAR α/γ agonists: Promises and pitfalls in type 2 diabetes

American Journal of Therapeutics

Volumn 14, Issue 1, 2007, Pages 49-62

  Ahmed, Intekhab ^a   Furlong, Kevin ^a   Flood, Jeremy ^a   Treat, Vanita P ^a   Goldstein, Barry J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Dyslipidemia; Glitazars; Insulin resistance; Metabolic syndrome; Thiazolidinediones

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; FATTY ACID; FENOFIBRATE; GEMFIBROZIL; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MK 0676; MURAGLITAZAR; NATEGLINIDE; NUCLEAR FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TESAGLITAZAR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; EDEMA; FATTY ACID METABOLISM; FIBRINOLYSIS; FLUID RETENTION; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMOBILIZATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MALIGNANT NEOPLASTIC DISEASE; MICROALBUMINURIA; MONOTHERAPY; MULTIFACTORIAL INHERITANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FAMILY; RESTENOSIS; REVIEW; RISK REDUCTION; SIDE EFFECT; TISSUE DISTRIBUTION; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CLOFIBRIC ACID; DIABETES MELLITUS, TYPE 2; HUMANS; PPAR ALPHA; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 33847122993     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000212890.82339.8d     Document Type: Review

References (123)

1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333-1346.
2. Kelly DE. Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev. 1995;3:366-377.
3. Schenider SH, Morgado A. Effects of fitness and physical training on carbohydrate metabolism and associated cardiovascular risk factors in patients with diabetes. Diabetes Rev. 1995;3:378-407.
4. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPAR gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26:76-80.
5. ADA Position Statement. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29(Suppl 1):S43-S48.
6. Taylor R. Causation of type 2 diabetes-the Gordian knot unravels. N Engl J Med. 2004;350:639-641.
7. Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350:664-671.
8. Moran A, et al. Differentiation of glucose toxicity from beta cell exhaustion during the evolution of defective insulin gene expression in the pancreatic islet cell line, HIT-T15. J Clin Invest. 1997;99:534-539.
9. ADA Position Statement. Standards of Medical Care in Diabetes - 2006. Diabetes Care. 2006;29(Suppl 1):S4-42.
10. ADA Position Statement. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27(Suppl 1):S68-S71.
11. Goldberg IJ. Why does diabetes increase atherosclerosis? I don't know! J Clin Invest. 2004;114:613-615.
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
13. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
14. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
16. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-342.
17. Evans RM, Barish GD, Wang YX. Nat. Med. 2004;10:355-361.
18. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endo Rev. 1999;20:649-688.
19. Greene ME, Blumberg B, McBride OW, et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Exp. 1995;4:281-299.
20. Sher T, Yi HF, McBride OW, et al. CDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated recpetor. Biochemistry. 1993;32:5598-5604.
21. Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR gamma in ischemia-reperfusion injury, inflammation and shock. Cardio Res. 2005;65:772-781.
22. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000;49:497-505.
23. Chinetti G, Fruchart JC, Staels B. Peoxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. Curr Opin Lipidol. 2003;14:459-468.
24. Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and gamma in the adult rat. Endocrinology. 1996;137:354-366.
25. Gosset P, Charbonnier AS, Staels B, et al. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol. 2001;31:2857-2865.
26. Gurnell M. PPARgamma and metabolism: insight from the study of human genetic variants. Clin Endocrinol (Oxf). 2003;59:267-277.
27. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89:200-206.
28. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type 2 diabetic patients. Diabetologia. 2001;44:2210-2219.
29. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24:710-719.
30. Wu Z, Xie Y, Morrison RF, et al. PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPaα during the conversion of 3T3 fibroblasts in adipocytes. J Clin Invest. 1998;101:22-32.
31. Lefebvre AM, Fievet C, Auwerx J, et al. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterisceler Thromb. 1997;17:1756-1764.
32. Brun RP, Forman BM, Ellis R, et al. Differential activation of adipogensis by multiple PPAR isoforms. Genes Dev. 1996;10:974-984.
33. Maeda N, Takahashi M, Kihara S, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094-2099.
34. Wilson-Fritch L, Nicoloro S, Chouinard M, et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest. 2004;114:1281-1289.
35. Rosenberg DE, Jabbour A, Goldstein BJ. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. Diabetes Obes Metab. 2005;7:642-653.
36. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004;25:4-7.
37. Picard F, Auwerx J. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr. 2002;22:167-197.
38. Hallakou S, Foufelle F, Doare L, et al. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation. Diabetologia. 1998;41:8:963-968.
39. Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 1998;101:1354-1361.
40. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol. 2001;280:E827-E847.
41. Ryden M, Dicker A, van Harmelen V, et al. Mapping of early signaling events in tumor necrosis factor-alpha-mediated lipolysis in human fat cells. J Biol Chem. 2002;277:1085-1091.
42. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care. 1999;22(Suppl 3):C25-C30.
43. Steppan CM, Bailey ST, Bhat S. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312.
44. Hainault I, Nebout G, Turban S. Adipose tissue specific increase in angiotensin expression and secretion in the obese (fa/fa) Zucker rat. Am J Physiol. 2002;282:E59-E66.
45. Mohammed Ali V, Goodrick S, Rawesh A. Subcutaneous adipose tissue releases interleuki-6, but not tumor necrosis factor-alpha in vivo. J Clin Endocrinol Metab. 1997;82:4196-4200.
46. Pickup JC, Chusney GD, Thomas SM, et al. Plasma interleukin-6, TNF alpha, and blood cytokines production in type 2 diabetes. Life Sci. 2000;67:291-300.
47. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004;89:2563-2568.
48. Phillips SA, Ciaraldi TP, Kong AP, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 2003;52:667-674.
49. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166-2170.
50. Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care. 2003;26:3148-3152.
51. Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and postprandial glucose in patients with type II diabetes. Diabetologia. 2000;43:278-284.
52. Bakst A, Schwartz S, Fischer JS, et al. Avandia worldwide awareness registryimproved metabolic control with initiation of rosiglitazone in a diabetes clinic setting. Diabetes. 2001;50(Suppl 2):A430.
53. Yamasaki Y, Kawamori R, Wasada T, et al. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM: AD-4833 Glucose Clamp Study Group, Japan. Tohoku J Exp Med. 1997;183:173-183.
54. Martens FM, Visseren FL, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 2002;62:1463-1480.
55. Wagstaff AJ, Goa KL. Rosiglitazone a review of its use in the management of type 2 diabetes mellitus. Drugs. 2002;62:1805-1837.
56. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342-1349.
57. DeFronzo RA, Goodman AM. Multicenter Metformin Study Group. Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
58. Yu JG, Kruszynska YT, Mulford MI, et al. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes. 1999;48:2414-2421.
59. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;134:61-71.
60. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998;21:160-178.
61. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547-1554.
62. White WB, Prisant K, Wright JT. Management of patients with hypertension and diabetes mellitus: advance in the evidence for intensive treatment. Am J Med. 2000;108:238-245.
63. Quinones MJ, Nicholas SB, Lyon CJ. Insulin resistance and the endothelium. Curr Diab Reports. 2005;5:246-253.
64. Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertension 1995;8:316-320.
65. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes. 1997;46:433-439.
66. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. New Eng J Med. 1994;331:1188-1193.
67. Sarafidis PA, Lasaridis AN, Nilsson PM, et al. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Metabolism: Clinical & Experimental. 2005;54:1236-1242.
68. Scherbaum W, Göke B, German Pioglitazone Study Group. Pioglitazone reduces blood pressure in patients with type-2-diabetes mellitus. Diabetes. 2001;50(Suppl 2):A462.
69. Satoh H, Tsukamoto K, Hasimoto Y, et al. Thiazolidinediones suppress endothelin-1 secretion from the bovine vascular endothelium: a new possible role of PPARgamma on vascular endothelial cells. Biochem Biophys Res Commun. 1999;254:757-763.
70. Fitzgerald SM, Kemp-Harper BK, Tare M, et al. Role of endothelium-derived hyperpolarizing factor in endothelial dysfunction during diabetes. Clin and Exper Pharm and Physiology. 2005;32:482-487.
71. Tooke J. The association between insulin resistance and endotheliopathy. Diabetes Obes Metab. 1999;1:S17-S22.
72. Pistrosch F, Passauer J, Fischer S. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 2004;27:484-490.
73. Mohanty P, Aljada A, Ghanim H. Rosiglitazone improves vascular reactivity, inhibits reactive oxygen species (ROS) generation, reduces p47phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): evidence of a potent anti-inflammatory effect. Diabetes. 2001;50:A68.
74. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemostais. 2005;3:1879-1883.
75. Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med. 2005;5:323-332.
76. Chu JW, Abbasi F, Lamendola C, et al. Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diabetes Vascular Dis Res. 2005;2:37-41.
77. Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diab Res Clin Prac. 2005;69:5-13.
78. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
79. Satoh N, Ogawa Y, Usui T. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26:2493-2499.
80. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004;89:2728-2735.
81. Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation: Part I. Circulation. 2003;108:1917-1923.
82. Marx N, Imhof A, Wierse G, et al. Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease. Circulation. 2003;107:1954-1957.
83. Mattock MB, Morrish NJ, Viberti G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992;41:736-741.
84. Toto RD. Heart disease in diabetic patients. Seminars in Nephrology. 2005;25:372-378.
85. Sarafidis PA, Lasaridis AN, Nilsson PM, et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertension. 2005;18:227-234.
86. Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endo Metab. 2004;286:E560-E567.
87. Narce M, Poisson JP. Novel PPARgamma-dependent and independent effects for thiazolidinediones. Curr Opin Lipidol. 2003;14:651-652.
88. Kawasaki F, Matsuda M, Kanda Y, et al. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am J Physiol Endo Metab. 103. 2005;288:E510-E518.
89. Fonseca VA, Rosenstock J, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes: A randomized controlled trial. JAMA. 2000;283:1695-1702.
90. Mudaliar S, Henry RR. Curr Opin Endocrinol Diabetes. 2002;9:285-302.
91. Guan Y, Hao C, Rao R, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005;11:861-866.
92. Spiegelman BM. PPAR-γ adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507-514.
93. Zanchi A, Chiolero A, Maillard M, et al. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab. 2004;89:1140-1145.
94. Fonseca VA. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med. 2003;115(Suppl 8A):42S-48S.
95. Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med. 2003;115(Suppl 8A):111S-115S.
96. St. John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25:2058-2064.
97. Nesto RW. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure. A Consensus Statement From the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941.
98. Rosenstock J, Goldstein BJ, Vinik AI, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab. 2006;8:49-57.
99. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. The Lancet. 2005;366:1279-1289.
100. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia. 2005;48:1726-1735.
101. Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation. 2003;107:636-642.
102. Pineda Torra I, Gervois P, Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol. 1999;10:151-159.
103. Hirotani M, Tsukamoto T, Bourdeaux J, et al. Stabilization of peroxisome proliferator-activated receptor alpha by the ligand. Biochem Biophys Res Commun. 2001;288:106-110.
104. Dunbar RL, Rader DJ. Demystifying triglycerides: a practical approach for the clinician. Cleveland Clin J Med. 2005;72:661-680.
105. Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527-550.
106. Barbier O, Pineda Torra I, Duguay Y, et al. Pleiotroopic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscl Thromb Vascular Biol. 2002;22:717-726.
107. Marx N, Sukhova GK, Collins T, et al. PPAR-alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99:3125-3131.
108. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85:394-402.
109. Goya K, Sumitani S, Xu X, et al. Peroxisome proliferators-activated receptor-alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2004;24:658-663.
110. Neve BP, Corseaux D, Chinetti G, et al. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 2001;103:207-212.
111. Durrington PN, Mackness MI, Bhatnagar D, et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type 22b hyperlipoproteinaemia. Atherosclerosis. 1998;138:217-225.
112. Koh KK, Han SH, Quon MJ, et al. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care. 2005;28:1419-1424.
113. Svec F, Porter JR. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med. 1998;218:174-191.
114. Peters JM, Zhou YC, Ram PA, et al. Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate. Mol Pharmacol. 1996;50:67-74.
115. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomized controlled trial. The Lancet. 2005;366:1849-1861.
116. Seber S, Ucak S, Basat O, et al. The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract. 2006;71(1):52-58.
117. Desai RC, Han W, Metzger EJ, et al. 5-aryl thiazolidine-2, 4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. Bioorg Med Chem Lett. 2003;13:2795-2798.
118. Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med. 2006;12:75-80.
119. Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005;27:1181-1195.
120. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4169B2_02_03-FDA- MedOff-Safety.pdf; http://www.fda.gov/ohrms/dockets/ac/05/slides/2005- 4169S2_01_01-BMS-Main.ppt; Accessed February 25, 2006.
121. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294:2581-2586.
122. Press Release, http://www.bms.com/news/press/data/fg_press_release_5930. html; Accessed February 25, 2006.
123. Fagerberg B, Edwards S, Halmos T, et al. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia. 2005;48:1716-1725.